Dkt. 55873-BA-PCT-US/JPW/AJM/AAB

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ann Marie Schmidt, et al.

U.S. Serial No.: 10/665,867

Filed: September 19, 2003

For : Extracellular RAGE Binding Protein (EN-

RAGE) and Uses Thereof

1185 Avenue of the Americas New York, New York 10036 January 6, 2004

Commissioner for Patents P.O. Box 1450 Alexandria VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with the duty of disclosure under 37 C.F.R. \$1.56, applicant directs the Examiner's attention to the following disclosures, which are listed on Form PTO-1449 (Exhibit A).

- U.S. Patent No. 5,688,653, November 18, 1997 (Ulrich, et al.);
- 2. U.S. Patent No. 5,864,018, January 26, 1999 (Morser, et al.);
- 3. U.S. Patent No. 5,976,832, November 2, 1999 (Hitomi, et al.);
- 4. Morser et al. PCT International Application No. PCT/EP97/01832, filed April 11, 1997, published October

Serial No.: 10/665,687

Filed : September 19, 2003

Page 2

23 1997; Publication No. WO 97/39121, Advanced Glycation Endproduct Receptor Peptides and Uses Thereof;

- 5. Morser et al. PCT International Application No. PCT/EP97/01834, filed April 11, 1997, published October 23 1997; Publication No. WO 97/39125, Antibodies Against the Advanced Glycation Endproduct Receptor and Uses Thereof;
- 6. Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. <u>Diabetes</u> 40:405-412;
- 7. Borchelt, D. R., et al. (1996). Familial Alzheimer's Disease-linked presentlin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013;
- 8. Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6):1699-1712;
- 9. Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications. <u>Diabetes Care</u> 15(12):1835-1842;
- 10. Cai, X-D., et al. (1993). Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259: 514-516;
- 11. Citron, M., et al. (1997). Mutant presentlins of Alzheimer's Disease increase production of 42-residue amyloid β -protein in both transfected cells and transgenic mice. Nature Medicine 3(1): 67-72;

Serial No.: 10/665,687

Filed : September 19, 2003

- 12. Dell'Angelica, E.C., et al. (1994). Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J. Biol. Chem. 269: 28929-28936;
- 13. Fahey, T., et al. (1991). Diabetes impairs the late inflammatory response to wound healing. <u>J. Surg. Res.</u> 50: 308-313;
- 14. Fu, M-X., et al. (1996). The advanced glycation end product, N^{ϵ} -(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. <u>J. Biol.</u> Chem. 271: 9982-9986;
- 15. Giardino, I., et al. (1994). Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J. Clin. Invest. 94: 110-117;
- 16. Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for vascular diseases. <u>Science</u> 272: 689-693;
- 17. Hofmann, M. A., et al. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell 97:889-901 (Exhibit 1);
- 18. Hori, O., et al. (1995). The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin J. Biol. Chem. 270: 25752-25761;

Serial No.: 10/665,687

Filed : September 19, 2003

- 19. Khoury, J. E., et al., (1994). Macrophages adhere to glucose-modified basement membrane collagen IV via their scavenger receptors. J. Biol. Chem. 269: 10197-10200;
- 20. Kuo, Y-M., et al. (1996). Water-soluble A β (N-40, N-42) oligomers in normal and Alzheimer Disease brains. <u>J. Biol. Chem.</u> 271(8): 4077-4081;
- 21. Lander, H. M., et al. (1997). Activation of the receptor for advanced glycation end products triggers a p21^{ras} dependent mitogen-activated protein kinase pathway regulated by oxidant stress. <u>J. Biol. Chem.</u> 272: 17810-17814;
- 22. Ledesma, M. D., et al. (1994). Analysis of microtubule-associated protein tau glycation in paired helical filaments. J. Biol. Chem. 269(34):21614-21619;
- 23. Li, J. and A.M. Schmidt (1997). Characterization and functional analysis of the promoter of RAGE, the receptor for advanced glycation end products. J. Biol. Chem. 272: 16498-16506;
- 24. Lorenzo, A. and B.A. Yanker (1994). β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Nat. Acad. Sci. USA 91: 12243-12247;
- 25. Mattson, M. P. and Y. Goodman (1995). Different amyloidogenic peptides share a similar mechanism of neurotoxicity involving reactive oxygen species and calcium. Brain Res. 676: 219-224;

Serial No.: 10/665,687

Filed : September 19, 2003

- 26. Miyata, T., et al. (1996). The receptor for advanced glycation end products (RAGE) is a central mediator of the interaction of AGE- β 2 Microglobulin with human mononuclear phagocytes via an oxidant-sensitive pathway. J. Clin. Invest. 98: 1088-1094;
- 27. Nakamura, Y., et al. (1993). Immunohistochemical localization of advanced glycosylation endproducts in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143(6): 1649-1656;
- 28. Neeper, M., et al. (1992). Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 267: 14998-15004;
- 29. Palinski, W., et al. (1995). Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits.

 Arterioscl. Thromb. and Vasc. Biol. 15(5): 571-582;
- 30. Park, L., et al. (1998). Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nature Medicine 4: 1025-1031;
- 31. Park, L., et al. (1997). A murine model of accelerated diabetic atherosclerosis: suppression by soluble receptor for advanced glycation endproducts. Circulation Supplement. Abstract 3079;
- 32. Reddy, S., et al. (1995). N^{ϵ} -(Carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34: 10872-10878;

Serial No.: 10/665,687

Filed : September 19, 2003

- 33. Renard, C., et al. (1997). Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol. Pharm. 52: 54-62;
- 34. Ritthaler, U., et al. (1995). Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease, Am. J. Pathol. 146: 688-694;
- 35. Roher, A. E., et al. (1996). Morphology and toxicity of $A\beta$ -(1-42) dimer derived from neuritic and vascular amyloid deposits of Alzheimer's Disease. <u>J. Biol. Chem.</u> 271(34): 20631-20635;
- 36. Schleicher, E. D., et al. (1997). Increased accumulation of the glycoxidation product N^{ϵ} -(carboxymethyl)lysine in human tissues in diabetes and aging. <u>J. Clin. Invest.</u> 99: 457-468;
- 37. Schmidt, A. M., et al. (1995). Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice.

 J. Clin. Invest. 96: 1395-1403;
- 38. Schmidt, A. M., et al. (1994). Receptor for advanced glycation endproducts (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins. Proc. Nat'l Acad. Sci. USA 91: 8807-8811;
- 39. Schmidt, A. M., et al. (1992).- Isolation and characterization of two binding proteins for advanced

Serial No.: 10/665,687

Filed : September 19, 2003

Page 7

glycosylation end products from bovine lung which are present on the endothelial cell surface. J. Biol. Chem. 267: 14987-14997;

- 40. Schmidt, A. M., et al. (1994). Cellular receptors for advanced glycation end products. <u>Arterioscler. Thromb.</u> 14:1521-1528;
- 41. Schmidt, A. M., et al. (1995). The dark side of glucose. (News and Views). Nature Medicine 1: 1002-1004;
- 42. Schmidt, A. M., et al. (1993). Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. <u>J. Clin.</u> Invest. 92: 2155-2168;
- 43. Schmidt, A. M., et al. (1997). The V-domain of receptor for advanced glycation endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetic complications. Circulation Supplement 96:#194, p. I-37;
- 44. Schmidt, A. M., et al. (1994). The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J. Biol. Chem. 269: 9882-9888;
- 45. Schmidt, A.M., et al. (1998). RAGE: a receptor with a taste for multiple ligands and varied pathophysiologic states. Hormones and Signaling 1:41-63;
- 46. Sell, D., et al. (1989). Structure elucidation of a senescene cross-link from human extracellular matrix;

Serial No.: 10/665,687

Filed : September 19, 2003

Page 8

implication of pentoses in the aging process. <u>J. Biol.</u> Chem. 264:21597-21602;

- 47. Soulis, T., et al. (1997). Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40: 619-628;
- 48. Turner, R.S., et al. (1997). Amyloids β_{40} and β_{42} are generated intracellularly in cultured human neurons and their secretion increases with maturation. J. Biol. Chem. 271(15): 8966-8970;
- 49. Vitek, M.P., et al. (1994). Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Nat'l Acad. Sci. USA 91: 4766-4770;
- 50. Vlassara, H., et al. (1995). Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Molec. Med. 1: 634-646;
- 51. Vlassara, H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab.
 Invest. 70: 138-151;
- 52. Vlassara, H., et al. (1995). Identification of Galectin-3 as a high affinity binding protein for advanced glycation end products. Arterisocler. Thromb. 14:1521-1528;
- 53. Wautier, J.-L., et al. (1996). Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy:

Serial No.: 10/665,687

Filed : September 19, 2003

Page 9

soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats. \underline{J} . Clin. Invest. 97: 238-243;

- 54. Wautier, J.-L., et al. (1996). Interaction of diabetic erythrocytes bearing advanced glycation endproducts with the endothelial receptor AGE induces generation of reactive oxygen intermediates and cellular dysfunction. Circulation Supplement 94(8): #4139;
- 55. Wu J., et al. (1997). The soluble receptor for advanced glycation endproducts (sRAGE) ameliorates impaired wound healing in diabetic mice. Plastic Surg. Res. Council Abstract #77, p. 43;
- 56. Yan, S. D., et al. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269: 9889-9897;
- 57. Yan, S. D., et al. (1996). RAGE and amyloid- β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691;
- 58. Yan, S. D., et al. (1997). Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease.

 Proc. Nat'l Acad. Sci. 94: 5296-5301.

The subject application is a continuation of and claims the benefit under 35 U.S.C. §120 of U.S. Serial No. 09/826,589, filed April 5, 2001, which is a continuation of PCT

Serial No.: 10/665,687

Filed : September 19, 2003

Page 10

International Application No. PCT/US99/23303, filed October 6, 1999, designating the United States of America, which is a continuation-in-part and claims priority of U.S. Serial No. 09/263,312, filed March 5, 1999, now U.S. Patent No. 6,555,340 B1, issued April 29, 2003, which is a continuation-in-part and claims priority of U.S. Serial No. 09/167,705, filed October 6, 1998, the contents of which are incorporated by reference in their entirety into the present application.

Above-listed references 1, 6-16, 19-33, 35-44, 47-51 and 53-58 were submitted to and considered by the United States Patent and Trademark Office in an Information Disclosure Statement filed in connection with U.S. Serial No. 09/167,705, filed October 6, 1998. Above-listed references 2, 18 and 34 were cited by the United States Patent and Trademark Office in an Office Action dated March 24, 1998 in connection with 09/167,705, filed October 6, 1998. Above-listed references 4 and 5 were submitted to and considered by the United States Patent and Trademark Office in a Supplemental Information Disclosure Statement filed on June 18, 2001 in connection with U.S. Serial No. 09/167,705, filed October 6, 1998. listed reference 3 was cited by the United States Patent and Trademark Office in an Office Action dated December 19, 2000 in connection with 09/263,312, filed March 5, 1999, now U.S. Patent No. 6,555,340 Bl, issued April 29, 2003. Above-listed references 45, 46 and 52 were submitted to and considered by United States Patent and Trademark Office Information Disclosure Statement filed in connection with U.S. Serial No. 09/826,589, filed April 5, 2001. Accordingly, under 37 C.F.R. §1.98(d) copies of these references are not required to be provided to the United States Patent and

Serial No.: 10/665,687

Filed : September 19, 2003

Page 11

Trademark Office, since they were previously submitted to or cited by the United States Patent and Trademark Office in an application relied upon for an earlier effective filing date under 35 U.S.C. §120. A copy of above-listed reference 17 is submitted herewith, as Exhibit 1.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invites the Examiner to telephone him at the number provided below.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450.

Alan J. Morrison

Reg. No. 37,399

John P. White
Registration No. 28,678
Alan J. Morrison
Registration No. 37,399
Attorneys for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
Tel. No. (212) 278-0400

Sheet 1 of 11

Form PTO-1449 Commerce

e Har Department of

Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB

Serial No. 10/665,867

Patent and Trademark Office

Applicant(s) Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003 Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	C	ocı	um	ent	Nu	mt	er	Date	Name	Class	Subclass	Filing Date If Appropriate
	5	6	8	8	6	5	3	11/18/97	Ulrich, et al.			
	5	8	6	4	0	1	8	1/26/99	Morser, et al.			
	5	9	7	6	8	3	2	11/2/99	Hitomi, et al.			

FOREIGN PATENT DOCUMENTS

												Transla	ation
		Docı	ıme	nt N	umt	er		Date	Country	Class	Subclass	Yes	No
 WO	9	7	3	9	1	2	1	10/23/97	PCT				
 WO	9	7	3	9	1	2	5	10/23/97	PCT				
													ļ

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

ļ	OTHER DOCUMENTS (Including Author, Title, Date, Fertilient Fages, Etc.)
	Baynes, J. W. (1991). Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412;
	Borchelt, D. R., et al. (1996). Familial Alzheimer's Disease-linked presentlin 1 variants elevate Aβ1-42/1-40 ratio in vitro and in vivo. Neuron 17: 1005-1013;
	Brett, J., et al. (1993). Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143(6):1699-1712;
	Brownlee, M. (1992). Glycation products and the pathogenesis of diabetic complications. Diabetes Care 15(12):1835-1842;
	Cai, X-D., et al. (1993). Release of excess amyloid β protein from a mutant amyloid β protein precursor. Science 259: 514-516;
	Citron, M., et al. (1997). Mutant presentlins of Alzheimer's Disease increase production of 42-residue amyloid β -protein in both transfected cells and transgenic mice. Nature Medicine 3(1): 67-72;

EXAMINER

DATE CONSIDERED

Sheet 2 of 11

Form PTO-14 TRADE Patent and Trademark Office

Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB Serial No. 10/665,867

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003 Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	D	Document Number			er	Date	Name	Class	Subclass	Filing l	Date ropriate		
· · ·	+-			╁		+-	H				 	1	
				_									
	\dashv		-	╁	\vdash	H	\vdash	<u> </u>				1	
			ļ	_			\sqcup						
				\top									
	-		\vdash	╄	_	-					-	 	
					1								
					-		I	FOREIGN	PATENT DOC	CUMENTS			
												Trans	lation
Examiner Initials	D	ocu	me	nt	Nui	nbo	er	Date	Name	Class	Subclass	Yes	No
1			П									1.	
			П		\Box								
					\vdash		\vdash					+	
			\Box		1 1						1	1	
				·-									
				.									
				-				-					
													
))) TH	ER	R D	000	CU		EN	TS (Includ	ling Author, Ti	tle, Date, Pert	inent Pages,	Etc.)	

•	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Dell'Angelica, E.C., et al. (1994). Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J. Biol. Chem. 269: 28929-28936;
	Fahey, T., et al. (1991). Diabetes impairs the late inflammatory response to wound healing. J. Surg. Res. 50: 308-313;
	Fu, M-X., et al. (1996). The advanced glycation end product, N^{ϵ} -(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J. Biol. Chem. 271: 9982-9986;
	Giardino, I., et al. (1994). Nonenzymatic glycosylation in vitro and in bovine endothelial cells alters basic fibroblast growth factor activity. J. Clin. Invest. 94: 110-117;
	Gibbons, G. H. and V. J. Dzau. (1996). Molecular therapies for vascular diseases. Science 272: 689-693.;
	Hofmann, M. A., et al. (1999). RAGE mediates a novel proinflammatory axis: a central cell surface receptor for s100/calgranulin polypeptides. Cell 97:889-901;

EXAMINER

DATE CONSIDERED

Sheet 3 of 11

Form PTO-1349

18ADE N.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB Serial No. 10/665,867

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date
September 19, 2003

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	C	ocu	me	nt i	Nur	nbe	er	Date	Name	Class	Subclass	Filing If App	Date ropriate	
				П										
			-	\vdash								1		
<u> </u>			-	\vdash								 		
	\perp	ļ	ļ	\perp								 		
										-			•	
	. 1		l		l		 [FOREIC	ON PATENT DOCU	JMENTS	.I.	1		
T										1		Trans	slation	
Examiner nitials		ocu	me	nt i	Nur	nbe	r	Date	Name	Class	Subclass	Yes	No	
	_											ļ		
(•	luding Author, Title		_	-		
	E	ro	du	cts	s	(R	AG	E) Is	995). The Recep a Cellular Bi 752-25761;					
									et al., (19	94). Mac	rophages	adhei	re t	
	g	lu	cos	se-	-mc	odi	Ĺf	ied b	asement membra	ane coll	agen IV	via	thei	
	S	scavenger receptors.							5. J. Biol. Chem. 269: 10197-10200; (1996). Water-soluble Aβ (N-40, N-4					
									. (1996). Wa and Alzheimer D					
								4081;	and Alzheimei i	Disease Di	ails. U.	DIOI.	CHem	
									al. (1997). A	ctivation	of the 1	cecept	or fo	
	a	dv	and	ced	b	g.	Ly	cation	end products	triggers	s a p21 ^{ra}	's dep	enden	
	n	iit	oge	en-	-ac	cti	Ĺν	ated p	rotein kinase	pathway				
į	l s	stress. J. Biol. Chem. 272: 17810-17814;												

EXAMINER

DATE CONSIDERED

(1994).

associated protein tau glycation in paired helical filaments.

Analysis

of microtubule-

al.

et

D.,

Biol. Chem. 269(34):21614-21619;

Ledesma,

	1	18	1 4			H					Sile.	01 1 01 11	
Form PT	Q-1	\$ 100 m	81	RAD	EMA	ŽU.	s.		nent of Commerce Trademark Office	Atty. Docke 575-55873-E US/JPW/AJ	BA-PCT-	Serial No. 10/665,86	
										Applicant(s Ann Marie) Schmidt, et	al.	
IN]	FOI							OSURE s if nece	CITATION ssary)	Filing Date September	19, 2003	Group Ai	rt Unit
	•	<u></u>	-					U.S.	PATENT DOCUMI	ENTS			
Examiner Initials		Doc	ume	ent i	Vui	mb	er	Date	Name	Class	Subclas	1	g Date propriate
			-	╬		 							
		-	+-	+		+-							
			+	+		╁┈							
			+			╁							
			†										
						1							,
		1					1	FOREIC	ON PATENT DOCU	MENTS			
								5	.,		6.1.1		islation
Examiner Initials		Doc	ume	ent i	Nui	mb	er	Date	Name	Class	Subclas	s Yes	No
			-	-	\dashv	-	Ш						
			+		\dashv		-						
			+										
						_		,					
											<u> </u>		
	07					» «			I II A (I TE)	D. 4. D	4: D	F4- \	
 .								•	luding Author, Title midt (1997). C		_	-	ctional
		ana	aly	sis	3	οſ	-	the p	romoter of RAGI cts. J. Biol. C	E, the r	receptor	for a	dvanced
		Loi	en	z0,	,	A.		and B	.A. Yanker (1	994). β-	amyloid	neurot	
			-						mation and is i 91: 12243-12247		by Cong	go red.	Proc.
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	-	Mat	ts	on,	,	Μ.	1	P. and	Y. Goodman (1	L995). Di			
									similar mechanis				
		Miy	/at	a,	Т	٠,	(et al.	(1996). The re	eceptor f	or adva	nced gl	ycation
		end	d p	ro	du	ct	s	(RAGE)	is a central r	mediator	of the	interac	tion of
		LAGE	. – 13		IVI i	CY	-00						7777 70
									n with human rathway. J. Clin.				
EXAMINE	R								n with human rathway. J. Clin. DATE CONSIDERED	Invest.			

Sheet 5 of 11

Form PTO-1449

U.S. Destartment of Commerce

Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB Serial No. 10/665,867

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003 **Group Art Unit**

U.S. PATENT DOCUMENTS

Examiner Initials	ı	Docu	ıme	nt l	Nur	mbe	er	Date	Name	Class	Subclass	Filing If App	Date ropriate
	\top		\top	1	\vdash	†	Г						
	+	+-	\vdash	+	\vdash	+-	\vdash			+			
		<u> -</u>		<u> </u>	<u> </u>	<u> </u>				_		<u> </u>	
									•				
				T	Г								
		+	十	+	\vdash	+	-						
	-	-	\vdash	┼	₩	┼	-					-	
			<u> </u>	<u></u>	<u> </u>	<u> </u>	<u>L</u>	FOREIG	 GN PATENT DOC	UMENTS			
								CINER	INTATENTEGE		T	Trans	lation
Examiner Initials		Doci	ıme	nt !	Nur	mbe	er	Date	Name	Class	Subclass	Yes	No
THE COLUMN TO TH	-	T	П		П		Г				1		
	_	T	\Box		П								
		+-	\forall		\vdash								
		\vdash	H		\vdash		 					· ·	
	-	+	++		\vdash		┢					 	
	+	+-	\vdash		+		-	· · · · · · · · · · · · · · · · · · ·					
		+	\vdash		┼┤		\vdash				+		
	TI			_		N/I		TC (Inc	luding Author, Tit	la Data Par	tinont Pages	Ftc.)	<u>1</u>
													•
	1	Nak	amı	ur	a,	Y	٠,	et al	. (1993). Immu	nohistoche	emical loc	alizat	10n 0:
	3	adv ~~~	and	ce	a +	g.	ΤА	cosyla	tion endproduc diabetes melli	ts in Co	oronary a T Dati	cheron	a and
		3ar 164					SU	ie in	draperes merri	.cus. Aiii	. U. Fati	101.	.43(0)
								et al.	(1992). Clo	ning and	expression	n of	a cel
		sur	·fa	ce.	1	rec	ce'	ptor 1	for advanced	glvcosvlat	ion end	produc	cts o
		oro	te:	in	s.	J		Biol. (Chem. 267: 1499	8-15004;		•	
	T i	Pal	in	sk	i,	N	ī.,	et a	al. (1995).	[mmunologi	cal evide	nce f	or the
	1	ore	sei	nc	e		οf	ad [.]	vanced glyco:	sylation	end p	roduct	s i
	6	atherosclerotic lesions of euglycemic rabbits. Arterioscl. Thromb. and Vasc. Biol. 15(5): 571-582;											
		ľhr	oml	<u>b.</u>	aı	nd	V	asc. B	iol. 15(5): 571	-582;			
]]	Par	k,	Ι	. ,		et	al.	(1998). Suppre	ession of	accelerat	ed di	abeti
									the soluble r		or advance	ed al?	catio
		end	pro	ō₫.	uc	ts	<u>. </u>	Natur	e Medicine 4: 1	025-1031;	51	+ a a -1-	- h - + -
									997). A muring suppression by				
									suppression by ts. Circulation				
		<u> 4 ⊤ Y</u>	<u>ca</u>	LΙ					DATE CONCIDENT		ic. Abstra	00 307	<u> </u>

EXAMINER

DATE CONSIDERED

Sheet 6 of 11

Form PTO-1439. RADE Patent and Trademark Office

Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB Serial No. 10/665,867

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003 Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials		Doci	u _. me	ent l	Nur	nbe	r	Date	Name	Class	Subclass	Filing If App	Date ropriate
		\perp	ļ	Ш			4						
]							
		T	T	П									
	+	+	+-	\vdash		\vdash							
		+	-	\vdash		\vdash	+				<u> </u>		
		\perp											
		\top	T				寸						
	+	+	+	Н		-	\dashv					-	
						<u>L</u> l.		ODEIC	 SN PATENT DOC	LIMENITO			-112
							r	OKER	IN PATENT DUC	UMENIS			
												Trans	slation
Examiner	1	Doc	ume	nt l	Nur	nbe	r	Date	Name	Class	Subclass	Yes	No
nitials	-	т-	1				\dashv						
		+-	-		\vdash	-	-						ļ
		 			\vdash		\dashv						
		 	\perp				4						
		_	1		1		_			•		<u> </u>	
							_						
												ļ. <u>.</u>	
													l
	TE	HEI	R D	OC	CU.	Μŀ	CN	TS (Inc	luding Author, Tit	de, Date, Pert	tinent Pages,	Etc.)	
		Red	ldy	, :	s.,	. ∈	t	al. (1995). N°-(Cai	boxymethyl)lysine i	s a do	minan
									end product (A	GE) antige	n in tiss	ue pro	teins
		Bic	ch	emi	ist	ry	3	4: 108	372-10878;				
									(1997). Reco				
									narmacokinetics	s in norma	l and dia	abetic	rats
		Mol	 - F F	Pha	arn	n.	52	: 54-6	al. (1995)	Evaross	ion of ro	aconto	re fo
	11.0					-				-		_	
									end products i hol. 146: 688		al occius	ive va	iscula.
											ئەئىيە بارسى	+ =	70 /1
									. (1996). Mo rom neuritic a				
									rom neuritic a $J. Biol. Che$				ILLS O
	- 1	Sch	le	ick	EL.	5	E	D	et al. (1997).	Increase	d accumul	ation	of th
									ct N^{ε} -(carboxy				
									ng. J. Clin.				

EXAMINER

DATE CONSIDERED

Sheet 7 of 11

Form PTO-1449 S. Department of Commerce atent and Trademark Office

Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB Serial No. 10/665,867

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003 Group Art Unit

U.S. PATENT DOCUMENTS

									U.S.	PATENT DOCUM	ENTS	1		
Examiner Initials		D	ocu	ıme	nt i	Nu	mbe	er	Date	Name	Class	Subclass	Filing If App	Date ropriate
					Π	Ĭ								
		\vdash		H	T									,
	-	-		├	╁		+						+	
					<u> </u>	_	1						 	
											*			
					T						,			
		-			╁		+						 	
				-	+	-	\vdash	_					+	
					<u></u>							<u> </u>		
]	FOREIC	SN PATENT DOCU	JMENTS			
													Trans	slation
Examiner		D	ocu	ıme	nt l	Nu	mbe	r	Date.	Name	Class	Subclass	Yes	No
Initials						1						-	-	
				-										
		-		-										-
				-		-							 	
		<u> </u>		-									-	-
		-		-		-						-		
		-				-								:
				Ļ		~~			1000 (T		D (D	· 4 D	174	<u> </u>
	O)									luding Author, Titl				
		S	ch	mi	dt	,	Α.	1	M., et	al. (1995).	Advanced	glycation	endpr	oducts
		1	nt	er	ac	tı	ng	W	ith th	eir endothelial sion molecule-	receptor	induce e	xpress	ion of
		^	as	cu o+	ld.	1 i	~ 1	. T	l aune	nd in mice. J.	Clin Inve	.) III Cui	.cu.eu 395-14	11umai
		3	ch	mi	dt		Δ	N	1 et	al. (1994). R	eceptor f	or advance	ed alv	cation
										nas a central r				
•										n in response				
										ci. USA 91: 880				
										aľ. (1992). Iso				
										s for advanced				
										are present on	the endo	thelial c	ell su	irface.
	<u> </u>	J	· ~ h	B1	<u>01</u>	•	Che	em *	. 26/:	14987-14997; al. (1994). C	0111122 2	acentars	for a	luance
										ar. (1994). C cts. Arterioscl				
	-	1 -	-						_	al. (1995). T				
										Medicine 1: 100		ide or gr	acose.	(140 44 5
	<u> </u>	سل				., 5	<i>,</i> •				,			

EXAMINER

DATE CONSIDERED

Form PTO-1449

partment of Commerce Patent and Trademark Office

Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB

Serial No. 10/665,867

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003 Group Art Unit

U.S. PATENT DOCUMENTS

							0.0.1.					
Examiner Initials	[Oocu	ımeı	nt Nu	ımb	er	Date	Name	Class	Subclass	Filing I	Date ropriate
								•				
												-
						\sqcap		14				
	-	\vdash	Н		+	\Box					<u> </u>	
	\dashv	┼		+	+	\vdash					-	<u> </u>
		\vdash	\vdash		-	H			-	-	 	
		-			+	\vdash						
						\coprod						
						F	OREIGN	PATENT DOC	CUMENTS			
											Trans	lation
Examiner Initials	I)ocu	ımeı	nt Nu	ımb	er	Date	Name	Class	Subclass	Yes	No

O	THER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Schmidt, A. M., et al. (1993). Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Invest. 92: 2155-2168;
	Schmidt, A. M., et al. (1997). The V-domain of receptor for advanced glycation endproducts (RAGE) mediates binding of AGEs: a novel target for therapy of diabetic complications. Circulation Supplement 96:#194, p. I-37;
	Schmidt, A. M., et al. (1994). The endothelial cell binding site for advanced glycation end products consists of a complex: an integral membrane protein and a lactoferrin-like polypeptide. J. Biol. Chem. 269: 9882-9888;
·	Schmidt, A.M., et al. (1998). RAGE: a receptor with a taste for multiple ligands and varied pathophysiologic states. Hormones and Signaling 1:41-63;
	Sell, D., et al. (1989). Structure elucidation of a senescene cross-link from human extracellular matrix; implication of pentoses in the aging process. J. Biol. Chem. 264:21597-21602;

EXAMINER

DATE CONSIDERED

Form PTO-1449

partment of Commerce ent and Trademark Office

Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB Serial No. 10/665,867

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003

70: 138-151;

Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials	Γ)ocu	men	t N	umb	er	Date	Name	Class	Subclass	Filing Date If Appropriate	
		<u> </u>										
	_			-	-	+-						
	+			+	\dashv							
										<u> </u>		
	1						*					

FOREIGN PATENT DOCUMENTS

Examiner Initials												Translation	
	D	ocu	me	ent	Nu	mb	er	Date	Name	Class	Subclass	Yes	No
					Τ								
						1							
					T								
					T		Τ		J. V. V.				
					T	T	Ť						
	\vdash		-		T		╁						
	Т			-	╁	t			*****				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Soulis, T., et al. (1997). Advanced glycation end products and their receptors co-localise in rat organs susceptible to diabetic microvascular injury. Diabetologia 40: 619-628;
Turner, R.S., et al. (1997). Amyloids β_{40} and β_{42} are generated intracellularly in cultured human neurons and their secretion increases with maturation. J. Biol. Chem. 271(15): 8966-8970;
Vitek, M.P., et al. (1994). Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc. Nat'l Acad. Sci. USA 91: 4766-4770;
Vlassara, H., et al. (1995). Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Molec. Med. 1: 634-646;
Vlassara, H., et al. (1994). Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications

EXAMINER

DATE CONSIDERED

Lab. Invest.

for diabetes and aging.

Sheet 10 of 11

Form PTO-1449
U.S. Separtment of Commerce
to Transport and Trademark Office

Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB

Serial No. 10/665,867

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003 Group Art Unit

U.S. PATENT DOCUMENTS

Examiner Initials		Doc	u me	ent N	Vur	nbe	r	Date	Name	Class	Subclass	Filing Date If Appropriate		
				T										
			+	+		\vdash	\dashv		10.00					
***			_	-		\sqcup	\dashv					 		
			+-				\dashv							
			-	+			\dashv							
													 	
			+	1		H								
						Ш		ODFIC	N PATENT DOC	HMENTS	<u> </u>			
								OKEIC	IN PATENT DOC	UNIENTS		Т —		
											Subclass	Translation		
Examiner		Doc	ume	ent N	Nur	nbe	r	Date	Name	Class		Yes	No	
Initials												+		
		-		-	\dashv		_							
			-				_							
												 	ļ	
			_		_									
												ļ		
_														
								L						
	O	HE	RI	000	CU	MI	EN	TS (Inc	luding Author, Tit	le, Date, Pert	inent Pages.	Etc.)		
		Vla	155	ara	۹.	H	_	et al	L. (1995). Ide	ntificatio	n of Gale	ectin-3	3 as a	
		hic							ding protein			ycatio		
		pro	du	cts	š .	Ar	cte	risocl	er. Thromb. 14	1:1521-1528	3;	<u>-</u>		
		Wau	ıti	er,		J	·L	., et a	al. (1996). Red	ceptor-med:	iated endo	thelia	l cell	
									abetic vascul					
									end product:			eabili	ty in	
									in. Invest. 97					
									et al. (199				abetio	
	erythrocytes bearing advanced glycation endproducts with endothelial receptor AGE induces generation of reactive ox													
		int	er	mec	dia			and o	cellular dysfu	inction. C	irculation	n Supp	lement	
						. ~ ~	•							
		94	(8)	: #				(1000	m) 3 1-3		S	1		
		94 Wu	(8) J.	; #	∍t	a]	L .		. The soluble) ameliorates		for advanc			

EXAMINER

DATE CONSIDERED

Form PTO-1449

partment of Commerce Patent and Trademark Office

Atty. Docket No. 575-55873-BA-PCT-US/JPW/AJM/AAB

Serial No. 10/665,867

Applicant(s)

Ann Marie Schmidt, et al.

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)

Filing Date September 19, 2003 **Group Art Unit**

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

•	Tible Document Community C
	Yan, S. D., et al. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem. 269: 9889-9897;
	Yan, S. D., et al. (1996). RAGE and amyloid- β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691;
	Yan, S. D., et al. (1997). Amyloid-β peptide-receptor for advanced glycation endproduct interaction elicits neuronal expression of macrophage-colony stimulating factor: a proinflammatory pathway in Alzheimer disease. Proc. Nat'l Acad. Sci. 94: 5296-5301;

EXAMINER

DATE CONSIDERED